Revvity(RVTY) - 2023 Q4 - Earnings Call Presentation

Innovation Transformation Performance 4 -6% y/y COVID: Includes $203M of AES Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink + DD + DD - HSD February 1, 2024 4Q23 Revenue Highlights V -7% | M&A: 0% | FX: 1% 28.0% 18.6% Reported: -8% | M&A: 0% | FX: 1% APPLIED GENOMICS REPRODUCTIVE HEALTH IMMUNODX $376 M 4Q23 revenue +DD -DD -LSD REVENUE AJUSTED OP MARGINS Fourth Quarter 2023 This presentation contains "forw ...